Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Co-administration with Preventive Monoclonal Antibody Treatment

Abhijeet Jakate, PhD

AHSAM 2020 - Poster session
Published on July 17, 2020

1 minute
2 minute

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Pharmacokinetic parameters of ubrogepant did not change following coadministration with erenumab or galcanezumab.
  • There did not appear to be any safety concerns during coadministration with both erenumab and galcanezumab.
  • The most common specific adverse event following study intervention was headache in 6 participants following erenumab injection.
  • Podcast by Abhijeet Jakate, PhD

Key messages

  • Pharmacokinetic parameters of ubrogepant did not change following coadministration with erenumab or galcanezumab.
  • There did not appear to be any safety concerns during coadministration with both erenumab and galcanezumab.
  • The most common specific adverse event following study intervention was headache in 6 participants following erenumab injection.

Podcast by Abhijeet Jakate, PhD

Abhijeet Jakate, PhD
Allergan plc
Madison, New Jersey

Abhijeet Jakate, PhD: Allergan plc (Employment) (Stock Shareholder (excluding mutual funds), Salary)

Headache
Migraine

Scan to open on your mobile device